Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Mochida Pharma Lowers Sales Estimate For 2010

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Mochida Pharmaceutical announces a midterm business plan for 2010, and the company estimates sales of ¥77 billion and ¥10.5 billion in profit. The sales goal is ¥5.5 billion lower than last year's actual result. Mochida will devote ¥10 billion to research and development. To reach the goals, Mochida plans to further strengthen strategic alliances, enter intractable diseases and cellular pharmaceutical areas and expand in the generics market. Mochida also plans to develop three drug candidates in domestic and overseas markets, focusing on core areas of diabetics and obesity, and sub-core area of chronic pain. (Click here for more - Japanese language

You may also be interested in...

Device Week, 23. October 2020 – Conference Spotlight TCT, HLTH

In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting. 

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Dr Reddy's Isolates Data Service Centers Among Preventive Actions Responding To Cyberattack




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts